Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

INTRODUCTION: Exercise limitation, dynamic hyperinflation, and exertional dyspnea are key features of symptomatic chronic obstructive pulmonary disease (COPD). We assessed the effects of glycopyrronium bromide (NVA237), a once-daily, long-acting muscarinic antagonist, on exercise tolerance in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Beeh, Kai M, Singh, Dave, Di Scala, Lilla, Drollmann, Anton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430121/
https://www.ncbi.nlm.nih.gov/pubmed/22973092
http://dx.doi.org/10.2147/COPD.S32451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430121/
https://www.ncbi.nlm.nih.gov/pubmed/22973092
http://dx.doi.org/10.2147/COPD.S32451

Ejemplares similares